AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 364285 — intervention group
Group type: COMPARATOR
Intervention: Remission maintenance with methotrexate
Number of subjects: 0
Study 30554751 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based screening for abnormal vaginal flora and urinary tract infections; treatment with oral clindamycin (300 mg twice daily for 5 days) for abnormal vaginal flora and cefixime (400 mg once daily for 3 days) or oral nitrofurantoin (100 mg twice daily for 7 days) for urinary tract infections.
Number of subjects: 9712
Study 30554751 — intervention group
Group type: COMPARATOR
Intervention: Control group received standard antenatal and postnatal care without the specific screening and treatment for infections.
Number of subjects: 9712
Study 30554751 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based screening for abnormal vaginal flora and urinary tract infections.
Number of subjects: 9712
Study 30554751 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of abnormal vaginal flora and urinary tract infections in the intervention group.
Number of subjects: 9712
Study 28072802 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sodium chloride solution added to lidocaine, triamcinolone, and hyaluronidase (hypertonic group)
Number of subjects: 246
Study 28072802 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional transforaminal epidural steroid injections)
Number of subjects: 246
Study 26026527 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic real-time evaluation of red blood cell elasticity using optical tweezers
Number of subjects: 150
Study 26026527 — intervention group
Group type: COMPARATOR
Intervention: Expert measurements of RBC elasticity
Number of subjects: 150
Study 23896831 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (cooling to 32-33°C for 48 hours)
Number of subjects: 19
Study 23896831 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 19
Study 23896831 — intervention group
Group type: COMPARATOR
Intervention: Controlled normothermia (as control)
Number of subjects: 19
Study 20642487 — intervention group
Group type: EXPERIMENTAL
Intervention: milnacipran 100 mg/day
Number of subjects: 2084
Study 20642487 — intervention group
Group type: EXPERIMENTAL
Intervention: milnacipran 200 mg/day
Number of subjects: 2084
Study 20642487 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2084
Study 19270861 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed contrast material (Omnipaque [Iohexol] 350 mg I/mL at 37 degrees C)
Number of subjects: 64
Study 19270861 — intervention group
Group type: COMPARATOR
Intervention: Room temperature contrast material (Omnipaque [Iohexol] 350 mg I/mL at 24 degrees C)
Number of subjects: 64
Study 17699431 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium (Na)/high-potassium (K) diet
Number of subjects: 40
Study 17699431 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Na/low-K diet
Number of subjects: 40
Study 15465995 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 12
Study 15465995 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose omega-3 fatty acids
Number of subjects: 12
Study 15465995 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose omega-3 fatty acids
Number of subjects: 12
Study 15465995 — intervention group
Group type: COMPARATOR
Intervention: Control group (bipolar subjects without omega-3)
Number of subjects: 12
Study 15465995 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects without bipolar disorder)
Number of subjects: 12
Study 11465517 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine treatment after a 4-day washout period
Number of subjects: 103
Study 11465517 — intervention group
Group type: COMPARATOR
Intervention: Immediate switch from SSRI to mirtazapine
Number of subjects: 103
Study 9716041 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 144
Study 9716041 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 144
Study 7991118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 2738209 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to monitor labor contractions and attendance at LaMaze classes (Study 1)
Number of subjects: 77
Study 2738209 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at LaMaze classes (Study 2)
Number of subjects: 77
Study 2738209 — intervention group
Group type: COMPARATOR
Intervention: Control group (Study 1)
Number of subjects: 77
Study 182347 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen treatments (Premarin, Provera, Provera and diethylstilbestrol, diethylstilbestrol alone)
Number of subjects: 1093
Study 182347 — intervention group
Group type: COMPARATOR
Intervention: Diethylstilbestrol or placebo
Number of subjects: 1093
Study 182347 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial triglyceride levels
Number of subjects: 1093
Study 182347 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial cholesterol levels
Number of subjects: 1093
Study 31318743 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthosis combined with exercise
Number of subjects: 0
Study 31318743 — intervention group
Group type: COMPARATOR
Intervention: Orthotic intervention only
Number of subjects: 0
Study 28830796 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib with capecitabine
Number of subjects: 537
Study 28830796 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine with placebo
Number of subjects: 537
Study 26537725 — intervention group
Group type: EXPERIMENTAL
Intervention: New dental nurse-led service using a brief negotiated interview based on motivational interviewing, delivered between enrollment and 6 weeks post-extraction.
Number of subjects: 224
Study 26537725 — intervention group
Group type: COMPARATOR
Intervention: Standard care (treatment as usual)
Number of subjects: 224
Study 23922146 — intervention group
Group type: EXPERIMENTAL
Intervention: TEVAR
Number of subjects: 140
Study 23922146 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical treatment alone
Number of subjects: 140
Study 21536812 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaiac-based FOB test (Hemoccult) with dietary restriction and three test cards for six consecutive samples
Number of subjects: 74592
Study 21536812 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaiac-based FOB test (Hemoccult)
Number of subjects: 74592
Study 19657295 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg.kg BW caffeine
Number of subjects: 9
Study 19657295 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg.kg BW caffeine
Number of subjects: 9
Study 19657295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 17244923 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 15 mg x kg(‐1) before heparin and before protamine injection
Number of subjects: 200
Study 17244923 — intervention group
Group type: COMPARATOR
Intervention: Autotransfusion (1‐2 units of autologous blood after cardiopulmonary bypass)
Number of subjects: 200
Study 17244923 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 200
Study 17244923 — intervention group
Group type: COMPARATOR
Intervention: Autotransfusion
Number of subjects: 200
Study 17244923 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid and autotransfusion
Number of subjects: 200
Study 14746622 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1% used twice daily
Number of subjects: 1550
Study 14746622 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroids (reactive treatment)
Number of subjects: 1550
Study 14746622 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in short-term studies)
Number of subjects: 1550
Study 11719310 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen therapy (NOT)
Number of subjects: 23
Study 11719310 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nocturnal oxygen therapy)
Number of subjects: 23
Study 9207636 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab (c7E3) bolus immediately before the intervention
Number of subjects: 489
Study 7535080 — intervention group
Group type: EXPERIMENTAL
Intervention: P-VEBEC regimen with rG-CSF 5 micrograms/kg/day for 4 consecutive days starting on day 2 of every week
Number of subjects: 67
Study 7535080 — intervention group
Group type: COMPARATOR
Intervention: P-VEBEC regimen without rG-CSF
Number of subjects: 67
Study 7535080 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RDI > 80%
Number of subjects: 67
Study 3310952 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 241
Study 3310952 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 241
Study 3310952 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 241
Study 3310952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 29370014 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person mindfulness-based resilience training (MBRT) for 6 weeks
Number of subjects: 60
Study 29370014 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered resiliency-based intervention for 6 weeks
Number of subjects: 60
Study 29370014 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 60
Study 27748432 — intervention group
Group type: EXPERIMENTAL
Intervention: FLIPUS+diclofenac sodium
Number of subjects: 106
Study 27748432 — intervention group
Group type: COMPARATOR
Intervention: Sham FLIPUS+diclofenac sodium
Number of subjects: 106
Study 25633497 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral reduced L-glutathione (GSH) 65 mg · kg(‐1) · day(‐1) divided into 3 doses per day for 6 months
Number of subjects: 44
Study 25633497 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral reduced L-glutathione (GSH)
Number of subjects: 44
Study 25633497 — intervention group
Group type: COMPARATOR
Intervention: Placebo (calcium citrate)
Number of subjects: 44
Study 24346292 — intervention group
Group type: EXPERIMENTAL
Intervention: PNF combined with ERB
Number of subjects: 20
Study 24346292 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 20
Study 20184615 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic medication (mostly pimozide)
Number of subjects: 182
Study 18568349 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 60
Study 16983923 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone (group A, n=14)
Number of subjects: 41
Study 16983923 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan and amiodarone (group B, n=15)
Number of subjects: 41
Study 16983923 — intervention group
Group type: EXPERIMENTAL
Intervention: WG plus irbesartan and amiodarone (group C, n=12)
Number of subjects: 41
Study 14570168 — intervention group
Group type: EXPERIMENTAL
Intervention: H2S olfactory stimuli
Number of subjects: 5
Study 14570168 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 trigeminal stimuli
Number of subjects: 5
Study 14570168 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral temperature
Number of subjects: 5
Study 14570168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleepiness
Number of subjects: 5
Study 14570168 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure, heart rate, nasal volume
Number of subjects: 5
Study 15353387 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 44
Study 15353387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 10199876 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) - 50 microgram bolus, then 50 ng.kg‐1.min‐1
Number of subjects: 15
Study 10199876 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (NTG) - 8 mg/min
Number of subjects: 15
Study 10199876 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP)
Number of subjects: 15
Study 10199876 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (NTG)
Number of subjects: 15
Study 10199876 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) and Nitroglycerin (NTG)
Number of subjects: 15
Study 10199876 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -6 mm Hg
Number of subjects: 15
Study 10199876 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -12 mm Hg
Number of subjects: 15
Study 7774991 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 mg)
Number of subjects: 15
Study 7774991 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (40 mg)
Number of subjects: 15
Study 7774991 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (20 mg)
Number of subjects: 15
Study 7774991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2213115 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic index derived from multivariate analysis of prognostic factors.
Number of subjects: 0
Study 2213115 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic index groups
Number of subjects: 0
Study 2213115 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent MRC trial verification
Number of subjects: 0
Study 356763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular methotrexate (MTX)
Number of subjects: 20
Study 356763 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 20
Study 31420467 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/pemetrexed plus apatorsen
Number of subjects: 155
Study 31420467 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin/pemetrexed plus placebo
Number of subjects: 155
Study 31420467 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatorsen in patients with high serum levels of Hsp27
Number of subjects: 155
Study 31420467 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients with high serum levels of Hsp27
Number of subjects: 155
Study 28452623 — intervention group
Group type: EXPERIMENTAL
Intervention: OFD+PRF
Number of subjects: 26
Study 28452623 — intervention group
Group type: COMPARATOR
Intervention: OFD
Number of subjects: 26
Study 25803679 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 J/cm² IPL treatment
Number of subjects: 20
Study 25803679 — intervention group
Group type: EXPERIMENTAL
Intervention: 13 J/cm² IPL treatment
Number of subjects: 20
Study 25803679 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 10J and 13J IPL treatment
Number of subjects: 20
Study 24105697 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (50 mg/kg bolus followed by 50 mg/kg infusion for 3 hours)
Number of subjects: 389
Study 24105697 — intervention group
Group type: COMPARATOR
Intervention: Placebo (bolus and infusion)
Number of subjects: 389
Study 21212307 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 759) performed 4 strengthening and 4 stretching exercises during supervised physical training lessons (7 per week).
Number of subjects: 770
Study 21212307 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 743) followed existing training syllabus warm-up exercises.
Number of subjects: 770
Study 21212307 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 759) performed exercises.
Number of subjects: 770
Study 19204597 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 kcal x kg(‐1) x wk(‐1)
Number of subjects: 310
Study 19204597 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 kcal x kg(‐1) x wk(‐1)
Number of subjects: 310
Study 19204597 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 kcal x kg(‐1) x wk(‐1)
Number of subjects: 310
Study 19204597 — intervention group
Group type: COMPARATOR
Intervention: 8 kcal x kg(‐1) x wk(‐1) vs 4 kcal x kg(‐1) x wk(‐1)
Number of subjects: 310
Study 19204597 — intervention group
Group type: COMPARATOR
Intervention: 12 kcal x kg(‐1) x wk(‐1) vs 4 kcal x kg(‐1) x wk(‐1)
Number of subjects: 310
Study 16881426 — intervention group
Group type: EXPERIMENTAL
Intervention: Acticoat
Number of subjects: 50
Study 16881426 — intervention group
Group type: COMPARATOR
Intervention: 1% silver sulfadiazine
Number of subjects: 50
Study 16881426 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 15682844 — intervention group
Group type: EXPERIMENTAL
Intervention: Scatter and cross-talk correction imaging protocol
Number of subjects: 14
Study 11412218 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of cooked tomatoes
Number of subjects: 112
Study 11412218 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased alcohol intake
Number of subjects: 112
Study 11412218 — intervention group
Group type: COMPARATOR
Intervention: Smoking
Number of subjects: 112
Study 11412218 — intervention group
Group type: COMPARATOR
Intervention: Coffee consumption
Number of subjects: 112
Study 11412218 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >75 years
Number of subjects: 112
Study 9402327 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth muscle tumors (leiomyosarcomas) in children with AIDS
Number of subjects: 8
Study 9402327 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV infection in smooth muscle cells
Number of subjects: 8
Study 8425280 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone treatment
Number of subjects: 203
Study 8425280 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 203
Study 29307259 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace social capital in provider burnout
Number of subjects: 40
Study 29307259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohesive work teams
Number of subjects: 40
Study 27461675 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Paclitaxel 175 mg/m² on day 1 and Carboplatin 450 mg on day 2 (PC)
Number of subjects: 60
Study 27461675 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: Docetaxel and Cisplatin 75 mg/m² each on day 1 and Ifosfamide 2 g/m² on day 1-3 along with Mesna (docetaxel-ifosfamide-cisplatin)
Number of subjects: 60
Study 25131839 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin extract (630mg thrice daily)
Number of subjects: 65
Study 25131839 — intervention group
Group type: COMPARATOR
Intervention: Placebo (thrice daily)
Number of subjects: 65
Study 23303874 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg daily)
Number of subjects: 37
Study 23303874 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg daily)
Number of subjects: 37
Study 23303874 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (15 mg daily)
Number of subjects: 37
Study 23303874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 19816719 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin copper foils of different thickness (5-200 µm) inserted between the teeth.
Number of subjects: 68
Study 20633377 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS (1000 pulses per day, 20,000 total)
Number of subjects: 51
Study 20633377 — intervention group
Group type: COMPARATOR
Intervention: 1 Hz rTMS (100 pulses per day, 2000 total)
Number of subjects: 51
Study 20633377 — intervention group
Group type: COMPARATOR
Intervention: Placebo rTMS
Number of subjects: 51
Study 15678413 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordered categorical doses of antidepressants
Number of subjects: 250
Study 12670818 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg.kg(‐1) iv (maximum dose 8 mg)
Number of subjects: 120
Study 11105399 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-mediated telecommunications system for family caregivers
Number of subjects: 0
Study 8669074 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 198
Study 8669074 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 198
Study 8669074 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 198
Study 1482735 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MAC halothane
Number of subjects: 40
Study 1482735 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MAC enflurane
Number of subjects: 40
Study 1482735 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MAC isoflurane
Number of subjects: 40
Study 1482735 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3 MAC isoflurane
Number of subjects: 40
Study 6374278 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH 1 (2,500 APTT units b.i.d.)
Number of subjects: 126
Study 6374278 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH 2 (5,000 APTT units b.i.d.)
Number of subjects: 126
Study 6374278 — intervention group
Group type: COMPARATOR
Intervention: UFH (5,000 APTT units b.i.d.)
Number of subjects: 126
Study 31347292 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarextumab with nab-paclitaxel and gemcitabine
Number of subjects: 0
Study 31347292 — intervention group
Group type: COMPARATOR
Intervention: Placebo with nab-paclitaxel and gemcitabine
Number of subjects: 0
Study 30128538 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐tDCS
Number of subjects: 74
Study 30128538 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 74
Study 30128538 — intervention group
Group type: COMPARATOR
Intervention: A‐tDCS vs Sham tDCS
Number of subjects: 74
Study 27435791 — intervention group
Group type: EXPERIMENTAL
Intervention: nifuratel-500 (500 mg nifuratel, intravaginal, 10 days)
Number of subjects: 142
Study 27435791 — intervention group
Group type: COMPARATOR
Intervention: nifuratel-250 (250 mg nifuratel, intravaginal, 10 days)
Number of subjects: 142
Study 27435791 — intervention group
Group type: EXPERIMENTAL
Intervention: nifuratel-500
Number of subjects: 142
Study 24394884 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1000 mg)
Number of subjects: 200
Study 24394884 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexketoprofen (50 mg)
Number of subjects: 200
Study 23018438 — intervention group
Group type: EXPERIMENTAL
Intervention: RAL
Number of subjects: 233
Study 20478753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (BTS collaborative methodology)
Number of subjects: 10
Study 20478753 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 10
Study 17562667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic group (exercise training at a target intensity that induced myocardial ischaemia)
Number of subjects: 22